Condition: Non-Small Cell Lung Cancer · Sponsor: Avistone Biotechnology Co., Ltd.
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
This description comes directly from the study's public registry record.
Avistone Clinical Study Information Center · 8610 84148921 · information.center@avistonebio.com
Always discuss trial participation with your own doctor first.
| Research Site | Fairfax, Virginia, United States | Recruiting |
| Research Site | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Research Site | Harbin, Heilongjiang, China | Recruiting |
| Research Site | Zhengzhou, Henan, China | Not Yet Recruiting |
| Study Site | Chengdu, Sichuan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07538804